{"filing":{"accession_number":"0001104659-26-090033","cik":"0000874716","ticker":"IDXX","company_name":"IDEXX LABORATORIES INC /DE","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"tm2622041d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/874716/000110465926090033/tm2622041d1_8k.htm"},"events":[{"id":23549,"run_id":21283,"accession_number":"0001104659-26-090033","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.99,"summary":"IDEXX announced its second quarter 2026 financial results on August 4, 2026, disclosing revenues of $1,217 million (10% reported growth, 9% organic), EPS of $4.27 (18% reported growth), and updated full-year 2026 guidance for revenue ($4,700–$4,745 million) and EPS ($14.69–$14.94). The full press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings releases. This is a material disclosure affecting investor assessment of the company's financial performance and outlook.","company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":23807,"accession_number":"0001104659-26-090033","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.99,"reasoning":"IDEXX announced its second quarter 2026 financial results on August 4, 2026, disclosing revenues of $1,217 million (10% reported growth, 9% organic), EPS of $4.27 (18% reported growth), and updated full-year 2026 guidance for revenue ($4,700–$4,745 million) and EPS ($14.69–$14.94). The full press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings releases. This is a material disclosure affecting investor assessment of the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T10:34:43.012664+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23807,"accession_number":"0001104659-26-090033","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.99,"reasoning":"IDEXX announced its second quarter 2026 financial results on August 4, 2026, disclosing revenues of $1,217 million (10% reported growth, 9% organic), EPS of $4.27 (18% reported growth), and updated full-year 2026 guidance for revenue ($4,700–$4,745 million) and EPS ($14.69–$14.94). The full press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for earnings releases. This is a material disclosure affecting investor assessment of the company's financial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T10:34:43.012664+00:00","company_name":"IDEXX LABORATORIES INC /DE","ticker":"IDXX","filing_date":"2026-08-04"}]}